20680-07-3

Usage

Urea derivative

A urea derivative is a compound that has a structure similar to urea (CO(NH2)2) but with modifications. In 1-methyl-3-(4-bromophenyl)urea, the urea structure is modified by the addition of a methyl group and a bromophenyl group.

Synthetic chemical compound

1-methyl-3-(4-bromophenyl)urea is a man-made compound, not found naturally in the environment, and is created through chemical reactions.

Use as an intermediate

1-methyl-3-(4-bromophenyl)urea is used as an intermediate in the production of pharmaceuticals and agrochemicals, meaning it is a precursor to the final product and undergoes further chemical reactions to create the desired end product.

Presence of a methyl group

A methyl group (CH3) is attached to the urea structure in 1-methyl-3-(4-bromophenyl)urea, which can affect its reactivity and properties.

Presence of a bromophenyl group

A bromophenyl group (C6H4Br) is part of the molecular structure of 1-methyl-3-(4-bromophenyl)urea, which can influence its reactivity, properties, and solubility.

Organic synthesis and research

1-methyl-3-(4-bromophenyl)urea is commonly used in organic synthesis and research due to its unique properties and reactivity, making it a valuable tool in the development of new chemicals and materials.

Applications in medicine and agriculture

The properties of 1-methyl-3-(4-bromophenyl)urea make it useful in various fields, including the production of pharmaceuticals and agrochemicals, which have applications in medicine and agriculture.

InChI:InChI=1/C8H9BrN2O/c1-10-8(12)11-7-4-2-6(9)3-5-7/h2-5H,1H3,(H2,10,11,12)

Upstream product

• 624-83-9 methyl isocyanate 
• 106-40-1 4-bromo-aniline 
• 103-71-9 phenyl isocyanate 
• 766-96-1 4-bromo-1-ethynylbenzene 
• 2493-02-9 4-bromophenyl isocyanate 
• 74-89-5 methylamine 

Downstream Products

• 38726-17-9 C₉H₈BrClN₂O₂ 
• 126381-32-6 3-(4-Bromo-phenyl)-1-(2-cyano-acetyl)-1-methyl-urea 
• 41881-61-2 N-methyl-N-ethylthio-N'-(4-bromophenyl)-urea 
• 1009622-76-7 1-[4-[4-(hydroxymethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-methylurea 
• 1009622-77-8 1-[4-[4-(cyclohexylsulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-methylurea 
• 1009622-78-9 1-[4-[4-(benzenesulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-methylurea 
• 1009622-83-6 3-methyl-1-[4-[4-[(3S)-3-methylmorpholin-4-yl]-6-(pyridin-4-ylsulfonylmethyl)pyrimidin-2-yl]phenyl]urea 
• 874290-99-0 1-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea 
• 1307885-40-0 1-(4-(7-(3-fluoro-4-methoxyphenyl)-1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)phenyl)-3-methylurea 
• 76802-51-2 1,1,3-Trimethyl-5-(4-bromophenyl)biuret 
• 19677-89-5 6-amino-1-(4-bromo-phenyl)-3-methyl-5-nitroso-1H-pyrimidine-2,4-dione 
• 19677-77-1 6-amino-3-methyl-1-(p-bromophenyl)uracil 
• 126381-42-8 (4-bromo-phenyl)-methyl-imidazolidinetrione 

Relevant academic research and scientific papers

Splitting a Substrate into Three Parts: Gold-Catalyzed Nitrogenation of Alkynes by C-C and C≡C Bond Cleavage

A gold-catalyzed nitrogenation of alkynes for the synthesis of carbamides and amino tetrazoles through C-C and C≡C bond cleavages is described. A diverse set of functionalized carbamide and amino tetrazole derivatives were selectively constructed under mild conditions. The chemoselectivity can be easily switched by the selection of the acid additives. The reaction is characterized by its broad substrate scope, direct construction of high value products, easy operation under air, and mild conditions at room temperature. This chemistry provides a way to transform alkynes by splitting the substrate into three parts.

QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8' are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/ the disease is cancer.

Pyridine derivatives and pharmaceutical compositions containing them

The invention relates to novel pyridyl derivatives, their use as medicaments, pharmaceutical formulations containing them and methods for their preparation.